Table Info

Table 2.

Several dermatoses treated with vitamin D analogs

Dermatosis	Treatment	Number of enrolled test patients	Response	Reference(s)
Epidermolytic acanthoma	Topical calcipotriol	1	Partial response. Some papules were present even after treatment. But those were lacking superficial keratotic material.	[135]
Clear cell acanthoma (CCA)	Topical calcipotriol	1	Complete and stable regression of CCA. Treatment has yielded complete regression after 2 months and no relapse after 1 year of treatment completion.	[136]
Bullous congenital ichthyosiform erythroderma (BCIE)	Topical maxacalcitol	1	Successful suppression of BCIE. A low dose (1.5 g/day) of topical maxacalcitol was sufficient, and there were no adverse effects on calcium metabolism.	[137]
Circumscribed plantar hypokeratosis	Topical calcipotriol	1	The lesion had been treated successfully and completely after 2 months.	[138]
Chronic kidney disease-associated pruritus	Calcipotriol solution	13	Partial response. Both validated modified pruritus assessment score (VMPAS) and visual analog scale (VAS) were significantly decreased (P < 0.05) after 2 and 4 weeks of calcipotriol treatment in comparison with a vehicle solution, respectively.	[139]
Recessive dystrophic epidermolysis bullosa (RDEB)	Vitamin D₃ as a supplement/formula/enteral feed	24	All RDEB patients require a supplement or a formula or enteral/sip feed of vitamin D to maintain sufficient serum levels. The dose required to maintain sufficient serum levels increased with age.	[140]
Dystrophic epidermolysis bullosa (DEB)	Topical calcipotriol	1	Diminished itchiness and pain with complete wound closure within 14 days.	[141]
Dystrophic epidermolysis bullosa (DEB)	Calcipotriol	12	Partial response. Out of the 12 DEB patients, 6 had significantly healed wound area at the 14th day compared to placebo (88.4% vs. 65.5%, P < 0.05).	[142]
Extramammary paget disease refractory	Calcipotriol	3	Partial response noted in 3/3 cases. Histopathological curing confirmed in 2/3 cases.	[143]
Sorafenib-associated hand-foot syndrome	Topical calcipotriol	1	Complete response. The lesions diminished during 14 days of treatment.	[144]
Linear atrophoderma of moulin	Topical calcipotriol	1	Partial response. After 3 months, lesion progression stopped but treated area partially improved. No further clinical improvement observed.	[145]
Oral leukoplakia	Calcipotriol gel	20	Partial response. Only 11 out of 20 patients had moderate to complete response.	[146]
Warts (facial verruca plana)	Topical calcipotriol	1	Complete response. Daily application completely resolved lesions after 8 weeks with no adverse reactions.	[147]
Disseminated superficial actinic porokeratosis (DSAP)	Calcipotriol and adapalene	1	Combination of calcipotriol and adapalene was successful in treating DSAP.	[148]
Axillary granular parakeratosis with osmidrosis	Topical maxacalcitol	1	Successful response. The pigmented lesion totally resolved within 5 months of treatment.	[149]

Declarations

Acknowledgments

The authors acknowledge the in-kind support provided by the Departments of Biosystems Technology, and Materials and Mechanical Technology at the Faculty of Technology, University of Sri Jayewardenepura, Homagama, Sri Lanka.

Author contributions

SSA: Conceptualization, Writing—original draft, Writing—review & editing. GAA: Writing—original draft, Writing—review & editing. RSD: Writing—review & editing.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Papadimitriou DT. The big vitamin D mistake. J Prev Med Public Health. 2017;50:278–81. [DOI] [PubMed] [PMC]

Wimalawansa SJ. Non-musculoskeletal benefits of vitamin D. J Steroid Biochem Mol Biol. 2018;175:60–81. [DOI] [PubMed]

Mostafa WZ, Hegazy RA. Vitamin D and the skin: focus on a complex relationship: a review. J Adv Res. 2014;6:793–804. [DOI] [PubMed] [PMC]

Zhang S, Miller DD, Li W. Non-musculoskeletal benefits of vitamin D beyond the musculoskeletal system. Int J Mol Sci. 2021;22:2128. [DOI] [PubMed] [PMC]

Wimalawansa SJ. Controlling chronic diseases and acute infections with vitamin D sufficiency. Nutrients. 2023;15:3623. [DOI] [PubMed] [PMC]

Wimalawansa SJ. Physiological basis for using vitamin D to improve health. Biomedicines. 2023;11:1542. [DOI] [PubMed] [PMC]

Wintermeyer E, Ihle C, Ehnert S, Stöckle U, Ochs G, de Zwart P, et al. Crucial role of vitamin D in the musculoskeletal system. Nutrients. 2016;8:319. [DOI] [PubMed] [PMC]

Wimalawansa SJ. Rapidly increasing serum 25(OH)D boosts the immune system, against infections-sepsis and COVID-19. Nutrients. 2022;14:2997. [DOI] [PubMed] [PMC]

Wimalawansa SJ. Vitamin D deficiency: effects on oxidative stress, epigenetics, gene regulation, and aging. Biology (Basel). 2019;8:30. [DOI] [PubMed] [PMC]

10.

Hilger J, Friedel A, Herr R, Rausch T, Roos F, Wahl DA, et al. A systematic review of vitamin D status in populations worldwide. Br J Nutr. 2014;111:23–45. [DOI] [PubMed]

11.

Lips P, de Jongh RT, van Schoor NM. Trends in vitamin D status around the world. JBMR Plus. 2021;5:e10585. [DOI] [PubMed] [PMC]

12.

Neville JJ, Palmieri T, Young AR. Physical determinants of vitamin D photosynthesis: a review. JBMR Plus. 2021;5:e10460. [DOI] [PubMed] [PMC]

13.

Wimalawansa SJ. Infections and autoimmunity—the immune system and vitamin D: a systematic review. Nutrients. 2023;15:3842. [DOI] [PubMed] [PMC]

14.

Chou Y, Alfarafisa NM, Ikezawa M, Khairani AF. Progress in the development of stem cell-derived cell-free therapies for skin aging. Clin Cosmet Investig Dermatol. 2023;16:3383–406. [DOI] [PubMed] [PMC]

15.

Russell-Goldman E, Murphy GF. The pathobiology of skin aging: new insights into an old dilemma. Am J Pathol. 2020;190:1356–69. [DOI] [PubMed] [PMC]

16.

Shin JW, Kwon SH, Choi JY, Na JI, Huh CH, Choi HR, et al. Molecular mechanisms of dermal aging and antiaging approaches. Int J Mol Sci. 2019;20:2126. [DOI] [PubMed] [PMC]

17.

Bocheva G, Slominski RM, Slominski AT. The impact of vitamin d on skin aging. Int J Mol Sci. 2021;22:9097. [DOI] [PubMed] [PMC]

18.

Tanveer MA, Rashid H, Tasduq SA. Molecular basis of skin photoaging and therapeutic interventions by plant-derived natural product ingredients: a comprehensive review. Heliyon. 2023;9:e13580. [DOI] [PubMed] [PMC]

19.

Agrawal R, Hu A, Bollag WB. The skin and inflamm-aging. Biology (Basel). 2023;12:1396. [DOI] [PubMed] [PMC]

20.

Ganceviciene R, Liakou AI, Theodoridis A, Makrantonaki E, Zouboulis CC. Skin anti-aging strategies. Dermatoendocrinol. 2012;4:308–19. [DOI] [PubMed] [PMC]

21.

Gromkowska-Kępka KJ, Puścion-Jakubik A, Markiewicz-Żukowska R, Socha K. The impact of ultraviolet radiation on skin photoaging — review of in vitro studies. J Cosmet Dermatol. 2021;20:3427–31. [DOI] [PubMed] [PMC]

22.

Shu P, Li M, Zhao N, Wang Y, Zhang L, Du Z. Efficacy and mechanism of retinyl palmitate against UVB-induced skin photoaging. Front Pharmacol. 2023;14:1278838. [DOI] [PubMed] [PMC]

23.

Guan LL, Lim HW, Mohammad TF. Sunscreens and photoaging: a review of current literature. Am J Clin Dermatol. 2021;22:819–28. [DOI] [PubMed] [PMC]

24.

Bernerd F, Passeron T, Castiel I, Marionnet C. The damaging effects of long UVA (UVA1) rays: a major challenge to preserve skin health and integrity. Int J Mol Sci. 2022;23:8243. [DOI] [PubMed] [PMC]

25.

Salminen A, Kaarniranta K, Kauppinen A. Photoaging: UV radiation-induced inflammation and immunosuppression accelerate the aging process in the skin. Inflamm Res. 2022;71:817–31. [DOI] [PubMed] [PMC]

26.

Manicone AM, McGuire JK. Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol. 2008;19:34–41. [DOI] [PubMed] [PMC]

27.

Han S, Jin SP, Oh JH, Seo EY, Park CH, Yoon HS, et al. Serum amyloid A1 secreted from UV-irradiated keratinocytes induces matrix metalloproteinase-1 in fibroblasts through toll-like receptor 4. Exp Dermatol. 2016;25:526–31. [DOI] [PubMed]

28.

Kim JM, Noh EM, Kwon KB, Hwang BM, Hwang JK, You YO, et al. Dihydroavenanthramide D prevents UV-irradiated generation of reactive oxygen species and expression of matrix metalloproteinase-1 and -3 in human dermal fibroblasts. Exp Dermatol. 2013;22:759–61. [DOI] [PubMed] [PMC]

29.

Zhang SY, Zhao YQ, Wang YM, Yang XR, Chi CF, Wang B. Gelatins and antioxidant peptides from Skipjack tuna (Katsuwonus pelamis) skins: purification, characterization, and cytoprotection on ultraviolet-A injured human skin fibroblasts. Food Biosci. 2022;50:102138. [DOI]

30.

Dawes JM, Antunes-Martins A, Perkins JR, Paterson KJ, Sisignano M, Schmid R, et al. Genome-wide transcriptional profiling of skin and dorsal root ganglia after ultraviolet-B-induced inflammation. PLoS One. 2014;9:e93338. [DOI] [PubMed] [PMC]

31.

Ansary TM, Hossain MR, Kamiya K, Komine M, Ohtsuki M. Inflammatory molecules associated with ultraviolet radiation-mediated skin aging. Int J Mol Sci. 2021;22:3974. [DOI] [PubMed] [PMC]

32.

Pacini L, Ceraolo MG, Venuti A, Melita G, Hasan UA, Accardi R, et al. UV radiation activates toll-like receptor 9 expression in primary human keratinocytes, an event inhibited by human papillomavirus 38 E6 and E7 oncoproteins. J Virol. 2017;91:e01123–17. [DOI] [PubMed] [PMC]

33.

Sun Z, Hornung V. cGAS-STING signaling. Curr Biol. 2022;32:R730–4. [DOI] [PubMed]

34.

Li C, Zhu Y, Liu W, Xiang W, He S, Hayashi T, et al. Impaired mitophagy causes mitochondrial DNA leakage and STING activation in ultraviolet B-irradiated human keratinocytes HaCaT. Arch Biochem Biophys. 2023;737:109553. [DOI] [PubMed]

35.

Reichrath J. Unravelling of hidden secrets: the role of vitamin D in skin aging. Dermatoendocrinol. 2012;4:241–4. [DOI] [PubMed] [PMC]

36.

Scott JF, Das LM, Ahsanuddin S, Qiu Y, Binko AM, Traylor ZP, et al. Oral vitamin D rapidly attenuates inflammation from sunburn: an interventional study. J Invest Dermatol. 2017;137:2078–86. [DOI] [PubMed] [PMC]

37.

Youn JI, Park BS, Chung JH, Lee JH. Photoprotective effect of calcipotriol upon skin photoreaction to UVA and UVB. Photodermatol Photoimmunol Photomed. 1997;13:109–14. [DOI] [PubMed]

38.

Camillo L, Gironi LC, Esposto E, Zavattaro E, Savoia P. Nicotinamide and calcipotriol counteract UVB-induced photoaging on primary human dermal fibroblasts. J Photochem Photobiol. 2022;12:100158. [DOI]

39.

Rybchyn MS, De Silva WGM, Sequeira VB, McCarthy BY, Dilley AV, Dixon KM, et al. Enhanced repair of UV-induced DNA damage by 1,25-dihydroxyvitamin D₃ in skin is linked to pathways that control cellular energy. J Invest Dermatol. 2018;138:1146–56. [DOI] [PubMed]

40.

De Silva WGM, McCarthy BY, Han J, Yang C, Holland AJA, Stern H, et al. The over-irradiation metabolite derivative, 24-hydroxylumister-ol₃, reduces UV-induced damage in skin. Metabolites. 2023;13:775. [DOI] [PubMed] [PMC]

41.

Dixon KM, Norman AW, Sequeira VB, Mohan R, Rybchyn MS, Reeve VE, et al. 1α,25(OH)₂-vitamin D and a nongenomic vitamin D analogue inhibit ultraviolet radiation-induced skin carcinogenesis. Cancer Prev Res (Phila). 2011;4:1485–94. [DOI] [PubMed]

42.

Reichrath J, Reichrath S, Vogt T, Römer K. Crosstalk between vitamin D and p53 signaling in cancer: an update. Adv Exp Med Biol. 2020;1268:307–18. [DOI] [PubMed]

43.

Yang C, Rybchyn MS, De Silva WGM, Matthews J, Holland AJA, Conigrave AD, et al. UV-induced DNA damage in skin is reduced by CaSR inhibition. Photochem Photobiol. 2022;98:1157–66. [DOI] [PubMed] [PMC]

44.

Chaiprasongsuk A, Janjetovic Z, Kim T-K, Jarrett SG, D’Orazio JA, Holick MF, et al. Protective effects of novel derivatives of vitamin D₃ and lumisterol against UVB-induced damage in human keratinocytes involve activation of Nrf2 and p53 defense mechanisms. Redox Biol. 2019;24:101206. [DOI] [PubMed] [PMC]

45.

He F, Ru X, Wen T. NRF2, a transcription factor for stress response and beyond. Int J Mol Sci. 2020;21:4777. [DOI] [PubMed] [PMC]

46.

Gupta R, Dixon KM, Deo SS, Holliday CJ, Slater M, Halliday GM, et al. Photoprotection by 1,25 dihydroxyvitamin D₃ is associated with an increase in p53 and a decrease in nitric oxide products. J Invest Dermatol. 2007;127:707–15. [DOI] [PubMed]

47.

Jagoda SV, Dixon KM. Protective effects of 1,25 dihydroxyvitamin D₃ and its analogs on ultraviolet radiation-induced oxidative stress: a review. Redox Rep. 2020;25:11–6. [DOI] [PubMed] [PMC]

48.

Niles JC, Wishnok JS, Tannenbaum SR. Peroxynitrite-induced oxidation and nitration products of guanine and 8-oxoguanine: structures and mechanisms of product formation. Nitric Oxide. 2006;14:109–21. [DOI] [PubMed]

49.

Virág L, Szabó E, Bakondi E, Bai P, Gergely P, Hunyadi J, et al. Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin. Exp Dermatol. 2002;11:189–202. [DOI] [PubMed]

50.

Chung HT, Pae HO, Choi BM, Billiar TR, Kim YM. Nitric oxide as a bioregulator of apoptosis. Biochem Biophys Res Commun. 2001;282:1075–9. [DOI] [PubMed]

51.

Hanada K, Sawamura D, Tamai K, Baba T, Hashimoto I, Muramatsu T, et al. Novel function of metallothionein in photoprotection: metallothionein-null mouse exhibits reduced tolerance against ultraviolet B injury in the skin. J Invest Dermatol. 1998;111:582–5. [DOI] [PubMed]

52.

Karasawa M, Hosoi J, Hashiba H, Nose K, Tohyama C, Abe E, et al. Regulation of metallothionein gene expression by 1 alpha,25-dihydroxyvitamin D3 in cultured cells and in mice. Proc Natl Acad Sci U S A. 1987;84:8810–3. [DOI] [PubMed] [PMC]

53.

Lee J, Youn JI. The photoprotective effect of 1,25-dihydroxyvitamin D₃ on ultraviolet light B-induced damage in keratinocyte and its mechanism of action. J Dermatol Sci. 1998;18:11–8. [DOI] [PubMed]

54.

Cojic M, Kocic R, Klisic A, Cvejanov-Kezunovic L, Kavaric N, Kocic G. A novel mechanism of vitamin D anti-inflammatory/antioxidative potential in type 2 diabetic patients on metformin therapy. Arch Med Sci. 2020;16:1004–12. [DOI] [PubMed] [PMC]

55.

Zhang Z, Wang YM, Qiu YT, Chi CF, Luo HY, Wang B. Gelatin from cartilage of Siberian sturgeon (Acipenser baerii): preparation, characterization, and protective function on ultraviolet-A-injured human skin fibroblasts. Front Mar Sci. 2022;9:925407. [DOI]

56.

Kong J, Hu XM, Cai WW, Wang YM, Chi CF, Wang B. Bioactive peptides from skipjack tuna cardiac arterial bulbs (II): protective function on UVB-irradiated HaCaT cells through antioxidant and anti-apoptotic mechanisms. Mar Drugs. 2023;21:105. [DOI] [PubMed] [PMC]

57.

Enk CD, Sredni D, Blauvelt A, Katz SI. Induction of IL-10 gene expression in human keratinocytes by UVB exposure in vivo and in vitro. J Immunol. 1995;154:4851–6. [PubMed]

58.

Debacq-Chainiaux F, Borlon C, Pascal T, Royer V, Eliaers F, Ninane N, et al. Repeated exposure of human skin fibroblasts to UVB at subcytotoxic level triggers premature senescence through the TGF-β1 signaling pathway. J Cell Sci. 2005;118:743–58. [DOI] [PubMed]

59.

Toniato E, Spinas E, Saggini A, Kritas SK, Caraffa A, Antinolfi P, et al. Immunomodulatory effects of vitamin D on skin inflammation. J Biol Regul Homeost Agents. 2015;29:563–7. [PubMed]

60.

Bhat GH, Guldin S, Khan MS, Yasir M, Prasad G. Vitamin D status in Psoriasis: impact and clinical correlations. BMC Nutr. 2022;8:115. [DOI] [PubMed] [PMC]

61.

Matushevskaya EV, Komissarenko IA, Vladimirova EV, Matushevskaya YI, Konev YV, Levchenko SV. The role of vitamin D in the prevention of pathology associated with psoriasis and metabolic syndrome. Med Counc. 2022;2022:8–16. [DOI]

62.

Ekiz Ö, Balta I, Şen BB, Dikilitaş MC, Özuǧuz P, Rifaioǧlu EN. Vitamin D status in patients with rosacea. Cutan Ocul Toxicol. 2014;33:60–2. [DOI] [PubMed]

63.

Mao R, Zhou G, Jing D, Liu H, Shen M, Li J. Vitamin D status, vitamin D receptor polymorphisms, and the risk of incident rosacea: insights from Mendelian randomization and cohort study in the UK biobank. Nutrients. 2023;15:3803. [DOI] [PubMed] [PMC]

64.

Akbaş A, Kilinç F, Şener S, Hayran Y. Vitamin D levels in patients with seborrheic dermatitis. Rev Assoc Med Bras (1992). 2023;69:e20230022. [DOI] [PubMed] [PMC]

65.

Rahimi S, Nemati N, Shafaei-Tonekaboni SS. Serum levels of 25-hydroxyvitamin D in patients with seborrheic dermatitis: a case-control study. Dermatol Res Pract. 2021;2021:6623271. [DOI] [PubMed] [PMC]

66.

Hattangdi-Haridas SR, Lanham-New SA, Wong WHS, Ho MHK, Darling AL. Vitamin D deficiency and effects of vitamin d supplementation on disease severity in patients with atopic dermatitis: a systematic review and meta-analysis in adults and children. Nutrients. 2019;11:1854. [DOI] [PubMed] [PMC]

67.

Shafiq AB, Chowdhury MR, Huda MF, Salahuddin AZ. Association of serum vitamin D concentration with the severity of patients with atopic dermatitis. Mymensingh Med J. 2023;32:666–70. [PubMed]

68.

Mesquita Kde C, Igreja AC, Costa IM. Atopic dermatitis and vitamin D: facts and controversies. An Bras Dermatol. 2013;88:945–53. [DOI] [PubMed] [PMC]

69.

Kim MR, Oji V, Valentin F, Traupe H, Nofer JR, Hausser I, et al. Vitamin D status in distinct types of ichthyosis: importance of genetic type and severity of scaling. Acta Derm Venereol. 2021;101:adv00546. [DOI] [PubMed] [PMC]

70.

Rodríguez-Manchón S, Pedrón-Giner C, Cañedo-Villarroya E, Muñoz-Codoceo RA, Hernández-Martín Á. Malnutrition in children with ichthyosis: recommendations for monitoring from a multidisciplinary clinic experience. J Am Acad Dermatol. 2021;85:144–51. [DOI] [PubMed]

71.

Soltani F, Rezazadeh Bazaz E, Mashhadi F, Saadati Rad MT, Humphries H, Ghaffari Z, et al. Evaluation of serum levels of vitamin D in patients with vitiligo: a case-control study. Tabari Biomed Stu Res J. 2023;5:3–10. [DOI]

72.

Karagün E, Ergin C, Baysak S, Erden G, Aktaş H, Ekiz Ö. The role of serum vitamin D levels in vitiligo. Postepy Dermatol Alergol. 2016;33:300–2. [DOI] [PubMed] [PMC]

73.

Saniee S, Zare AG, Radmehr A. Zinc, vitamin D, and TSH levels in patients with vitiligo. J Clin Pract Res. 2019;41:148–52. [DOI] [PMC]

74.

Kayo J, Al Shibli N. Vitamin D deficiency and the pathophysiology of skin disorders. Int J Clin Case Stud. 2023;2.

75.

Dasankunju BB, Nair PS, George AE. Serum vitamin D levels and alopecia areata: a comparative cross-sectional study. J Skin Sex Transm Dis. 2023;5:36–9.

76.

Thompson JM, Mirza MA, Park MK, Qureshi AA, Cho E. The role of micronutrients in alopecia areata: a review. Am J Clin Dermatol. 2017;18:663–79. [DOI] [PubMed] [PMC]

77.

Palmer DJ. Vitamin D and the development of atopic eczema. J Clin Med. 2015;4:1036–50. [DOI] [PubMed] [PMC]

78.

Seetan K, Eldos B, Saraireh M, Omari R, Rubbai Y, Jayyusi A, et al. Prevalence of low vitamin D levels in patients with Hidradenitis suppurativa in Jordan: A comparative cross-sectional study. PLoS One. 2022;17:e0265672. [DOI] [PubMed] [PMC]

79.

Formisano E, Proietti E, Borgarelli C, Pisciotta L. Psoriasis and vitamin D: a systematic review and meta-analysis. Nutrients. 2023;15:3387. [DOI] [PubMed] [PMC]

80.

Wang HY, Jiang DQ, Kang CZ, Wang S, Lyu CG, Zhang Y, et al. Research progress and prospect of endophytes from medicinal plant Atractylodes lancea. Zhongguo Zhong Yao Za Zhi. 2021;46:4930–5. Chinese. [DOI] [PubMed]

81.

Dai Q, Zhang Y, Liu Q, Zhang C. Efficacy and safety of vitamin D supplementation on psoriasis: a systematic review and meta-analysis. PLoS One. 2023;18:e0294239. [DOI] [PubMed] [PMC]

82.

Spencer RK, Jin JQ, Elhage KG, Davis MS, Liao W, Bhutani T. Management of plaque psoriasis in adults: clinical utility of tapinarof cream. Psoriasis (Auckl). 2023;13:59–69. [DOI] [PubMed] [PMC]

83.

Pokharel R, Agrawal S, Pandey P, Lamsal M. Assessment of vitamin D level in patients with psoriasis and its correlation with disease severity: a case-control study. Psoriasis (Auckl). 2022;12:251–8. [DOI] [PubMed] [PMC]

84.

Mason AR, Mason J, Cork M, Dooley G, Hancock H. Topical treatments for chronic plaque psoriasis. Cochrane Database Syst Rev. 2013:CD005028. [DOI] [PubMed]

85.

Chandy RJ, Dao DD, Rivis CC, Shan DM, Feldman SR. Noncorticosteroid topical therapies for the treatment of plaque psoriasis: a narrative review. J Pharm Technol. 2023;39:247–55. [DOI] [PubMed]

86.

Zhao Y, Asahina A, Asawanonda P, Frez ML, Imafuku S, Hyun Kim D, et al. Systematic review and practical guidance on the use of topical calcipotriol and topical calcipotriol with betamethasone dipropionate as long-term therapy for mild-to-moderate plaque psoriasis. J Dermatol. 2021;48:940–60. [DOI] [PubMed]

87.

Morimoto S, Yoshikawa K, Kozuka T, Kitano Y, Imanaka S, Fukuo K, et al. An open study of vitamin D3 treatment in psoriasis vulgaris. Br J Dermatol. 1986;115:421–9. [DOI] [PubMed]

88.

Smith EL, Pincus SH, Donovan L, Holick MF. A novel approach for the evaluation and treatment of psoriasis. Oral or topical use of 1,25-dihydroxyvitamin D₃ can be a safe and effective therapy for psoriasis. J Am Acad Dermatol. 1988;19:516–28. [DOI] [PubMed]

89.

Huckins D, Felson DT, Holick M. Treatment of psoriatic arthritis with oral 1,25-dihydroxyvitamin D₃: a pilot study. Arthritis Rheum. 1990;33:1723–7. [DOI] [PubMed]

90.

Perez A, Raab R, Chen TC, Turner A, Holick MF. Safety and efficacy of oral calcitriol (1,25-dihydroxyvitamin D₃) for the treatment of psoriasis. Br J Dermatol. 1996;134:1070–8. [PubMed]

91.

Park BW, Ha JM, Cho EB, Jin JK, Park EJ, Park HR, et al. A study on vitamin D and cathelicidin status in patients with rosacea: serum level and tissue expression. Ann Dermatol. 2018;30:136–42. [DOI] [PubMed] [PMC]

92.

Berth-Jones J, Adnitt PI. Topical calcipotriol is not effective in facial seborrhoeic dermatitis. J Dermatolog Treat. 2001;12:179. [DOI] [PubMed]

93.

Dimitrova J. The effect of vitamin d supplementation on recurrences of seborrheic dermatitis. Int J Curr Adv Res. 2017;6:2446–8. [DOI]

94.

Tadaki T, Kato T, Tagami H. Topical active vitamin D₃ analogue, 1,24-dihydroxycholecalciferol, an effective new treatment for facial seborrhoeic dermatitis. J Dermatolog Treat. 1996;7:139–41. [DOI]

95.

Basak PY, Ergin S. Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp. J Eur Acad Dermatol Venereol. 2001;15:86–8. [DOI] [PubMed]

96.

Yap FB. The role of combination calcipotriol plus betamethasone dipropionate gel in the treatment of moderate-to-severe scalp seborrhoeic dermatitis. Sultan Qaboos Univ Med J. 2018;18:e520–3. [DOI] [PubMed] [PMC]

97.

Park JS, Kim M, Sol IS, Lee KS, Park S, Yang HJ, et al. Effect of vitamin D on the treatment of atopic dermatitis with consideration of heterogeneities: meta-analysis of randomized controlled trials. Allergy Asthma Immunol Res. 2023;15:262–70. [DOI] [PubMed] [PMC]

98.

Çiçek F, Köle MT. Evaluation of the impact of serum vitamin D levels on the scoring atopic dermatitis index in pediatric atopic dermatitis. Children (Basel). 2023;10:1522. [DOI] [PubMed] [PMC]

99.

Imoto RR, Uber M, Abagge KT, Lima MN, Rosário NA, de Carvalho VO. Vitamin D supplementation and severity of atopic dermatitis: pre-post assessment. Allergol Immunopathol (Madr). 2021;49:66–71. [DOI] [PubMed]

100.

Garibeh E, Bondar S, Tokarchuk NI, Vyzgha YV. Charactirestics of vitamin D level in patients with atopic dermatitis. Medicni Perspekt. 2022;27:108–14. [DOI]

101.

Han TY, Kong TS, Kim MH, Chae JD, Lee JH, Son SJ. Vitamin D status and its association with the SCORAD score and serum LL-37 level in Korean adults and children with atopic dermatitis. Ann Dermatol. 2015;27:10–4. [DOI] [PubMed] [PMC]

102.

Baek JH, Shin YH, Chung IH, Kim HJ, Yoo EG, Yoon JW, et al. The link between serum vitamin D level, sensitization to food allergens, and the severity of atopic dermatitis in infancy. J Pediatr. 2014;165:849–54.e1. [DOI] [PubMed]

103.

Lara-Corrales I, Huang CM, Parkin PC, Rubio-Gomez GA, Posso-De Los Rios CJ, Maguire J, et al. Vitamin D level and supplementation in pediatric atopic dermatitis: a randomized controlled trial. J Cutan Med Surg. 2019;23:44–9. [DOI] [PubMed]

104.

Daniluk U, Filimoniuk A, Kowalczuk-Krystoń M, Alifier M, Karpińska J, Kaczmarski MG, et al. Association of antioxidants and vitamin D level with inflammation in children with atopic dermatitis. Int J Dermatol. 2019;58:1056–61. [DOI] [PubMed]

105.

Mansour NO, Mohamed AA, Hussein M, Eldemiry E, Daifalla A, Hassanin S, et al. The impact of vitamin D supplementation as an adjuvant therapy on clinical outcomes in patients with severe atopic dermatitis: a randomized controlled trial. Pharmacol Res Perspect. 2020;8:e00679. [DOI] [PubMed] [PMC]

106.

Takeichi T, Akiyama M. Inherited ichthyosis: non-syndromic forms. J Dermatol. 2016;43:242–51. [DOI] [PubMed]

107.

Fischer J, Bourrat E. Genetics of inherited ichthyoses and related diseases. Acta Derm Venereol. 2020;100:adv00096. [DOI] [PubMed] [PMC]

108.

Frascari F, Dreyfus I, Rodriguez L, Gennero I, Ezzedine K, Salles J, et al. Prevalence and risk factors of vitamin D deficiency in inherited ichthyosis: a French prospective observational study performed in a reference center. Orphanet J Rare Dis. 2014;9:127. [DOI] [PubMed] [PMC]

109.

Sethuraman G, Marwaha RK, Challa A, Yenamandra VK, Ramakrishnan L, Thulkar S, et al. Vitamin D: a new promising therapy for congenital ichthyosis. Pediatrics. 2016;137:e20151313. [DOI] [PubMed]

110.

Thacher TD, Fischer PR, Pettifor JM, Darmstadt GL. Nutritional rickets in ichthyosis and response to calcipotriene. Pediatrics. 2004;114:e119–23. [DOI] [PubMed]

111.

Mahmmod Z, Ismael DK. Vitamin D Deficiency in patients with vitiligo: a cross-sectional study from basrah, Iraq. Cureus. 2021;13:e20733. [DOI] [PubMed] [PMC]

112.

Upala S, Sanguankeo A. Low 25-hydroxyvitamin D levels are associated with vitiligo: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2016;32:181–90. [DOI] [PubMed]

113.

Zhang JZ, Wang M, Ding Y, Gao F, Feng YY, Yakeya B, et al. Vitamin D receptor gene polymorphism, serum 25-hydroxyvitamin D levels, and risk of vitiligo: a meta-analysis. Medicine (Baltimore). 2018;97:e11506. [DOI] [PubMed] [PMC]

114.

Kim TE, Kim SK, Shin MK, Jeong KH, Lee MH. Serum 25-hydroxy vitamin D levels and association of vitamin D receptor gene polymorphisms in vitiligo. J Korean Med Sci. 2022;37:e110. [DOI] [PubMed] [PMC]

115.

Al-Smadi K, Ali M, Alavi SE, Jin X, Imran M, Leite-Silva VR, et al. Using a topical formulation of vitamin D for the treatment of vitiligo: a systematic review. Cells. 2023;12:2387. [DOI] [PubMed] [PMC]

116.

Ahmed M, Khan AL, Alam MS, Wahab MA. Role of topical calcipotriol to potentiate the effect of photochemotherapy (PUVA) in treatment of vitiligo. J Armed Forces Med Coll. 2022;18:23–5.

117.

Liu X, Yao Z, Wang Y, Chai L, Zhou X. Vitamin D analogs combined with different types of phototherapy in the treatment of vitiligo: a systematic review of randomized trials and within-patient studies. Int Immunopharmacol. 2022;109:108789. [DOI] [PubMed]

118.

Kim JC, Kim HR, Park JS, Lee SY, Kim HO, Park CW, et al. Vitamin D supplementation can enhance therapeutic effects of excimer laser in patients with vitiligo. J Cosmet Dermatol. 2023;23:839–48. [DOI] [PubMed]

119.

Zhou C, Li X, Wang C, Zhang J. Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol. 2021;61:403–23. [DOI] [PubMed]

120.

Waśkiel-Burnat A, Osińska M, Salińska A, Blicharz L, Goldust M, Olszewska M, et al. The role of serum Th1, Th2, and Th17 cytokines in patients with alopecia areata: clinical implications. Cells. 2021;10:3397. [DOI] [PubMed] [PMC]

121.

Gil-Quiñones SR, Sepúlveda-Pachón IT, Sánchez Vanegas G, Gutierrez-Castañeda LD. Effect of PTPN22, FAS/FASL, IL2RA and CTLA4 genetic polymorphisms on the risk of developing alopecia areata: a systematic review of the literature and meta-analysis. PLoS One. 2021;16:e0258499. [DOI] [PubMed] [PMC]

122.

Fukuyama M, Ito T, Ohyama M. Alopecia areata: current understanding of the pathophysiology and update on therapeutic approaches, featuring the Japanese Dermatological Association guidelines. J Dermatol. 2022;49:19–36. [DOI] [PubMed]

123.

Chu CH, Cheng YP, Chan JYL. Alopecia areata after vaccination: recurrence with rechallenge. Pediatr Dermatol. 2016;33:e218–9. [DOI] [PubMed]

124.

Scollan ME, Breneman A, Kinariwalla N, Soliman Y, Youssef S, Bordone LA, et al. Alopecia areata after SARS-CoV-2 vaccination. JAAD Case Rep. 2022;20:1–5. [DOI] [PubMed] [PMC]

125.

Reinhold M. Relationship of stress to the development of symptoms in alopecia areata and chronic urticaria. Br Med J. 1960;1:846–9. [DOI] [PubMed] [PMC]

126.

Lee S, Lee H, Lee CH, Lee WS. Comorbidities in alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80:466–77.e16. [DOI] [PubMed]

127.

d’Ovidio R, Vessio M, d’Ovidio FD. Reduced level of 25-hydroxyvitamin D in chronic/relapsing alopecia areata. Dermatoendocrinol. 2013;5:271–3. [DOI] [PubMed] [PMC]

128.

Nancy AL, Yehuda S. Prediction and prevention of autoimmune skin disorders. Arch Dermatol Res. 2009;301:57–64. [DOI] [PubMed]

129.

Xie Z, Komuves L, Yu QC, Elalieh H, Ng DC, Leary C, et al. Lack of the vitamin D receptor is associated with reduced epidermal differentiation and hair follicle growth. J Invest Dermatol. 2002;118:11–6. [DOI] [PubMed]

130.

Narang T, Daroach M, Kumaran MS. Efficacy and safety of topical calcipotriol in management of alopecia areata: a pilot study. Dermatol Ther. 2017;30:e12464. [DOI] [PubMed]

131.

Çerman AA, Solak SS, Altunay İ, Küçükünal NA. Topical calcipotriol therapy for mild-to-moderate alopecia areata: a retrospective study. J Drugs Dermatol. 2015;14:616–20. [PubMed]

132.

Gupta ML, Singh S, Hasan Khan B. Comparative Evaluation of efficacy between topical calcipotriol used along with topical clobetasol and topical clobetasol monotherapy in treatment of alopecia areata: a randomised clinical trial. J Clin Diagnostic Res. 2021;15:WC05–8. [DOI]

133.

Alam M, Amin SS, Adil M, Arif T, Zahra FT, Varshney I. Comparative study of efficacy of topical mometasone with calcipotriol versus mometasone alone in the treatment of alopecia areata. Int J Trichology. 2019;11:123–7. [DOI] [PubMed] [PMC]

134.

Rashad AF, Elgamal E, Fouda I. Intralesional vitamin D3 in treatment of alopecia areata: a randomized controlled clinical trial. J Cosmet Dermatol. 2022;21:4617–22. [DOI] [PubMed]

135.

Batalla A, Carpintero ML, De la Torre C. Disseminated epidermolytic acanthoma with partial response to calcipotriol ointment. J Dermatol. 2013;40:144–5. [DOI] [PubMed]

136.

Scanni G, Pellacani G. Topical calcipotriol as a new therapeutic option for the treatment of clear cell acanthoma. An Bras Dermatol. 2014;89:803–5. [DOI] [PubMed] [PMC]

137.

Umekoji A, Fukai K, Ishii M. A case of mosaic-type bullous congenital ichthyosiform erythroderma successfully treated with topical maxacalcitol, a vitamin D3 analogue. Clin Exp Dermatol. 2008;33:501–2. [DOI] [PubMed]

138.

Batalla A, de la Torre C. Circumscribed plantar hypokeratosis responding to topical calcipotriol. J Dermatol Case Rep. 2013;7:129–31. [DOI] [PubMed] [PMC]

139.

Jung KE, Woo YR, Lee JS, Shin JH, Jeong JU, Koo DW, et al. Effect of topical vitamin D on chronic kidney disease-associated pruritus: an open-label pilot study. J Dermatol. 2015;42:800–3. [DOI] [PubMed]

140.

Yerlett N, Loizou A, Bageta M, Petrof G, Martinez AE. Establishing an appropriate level of vitamin D supplementation in paediatric patients with recessive dystrophic epidermolysis bullosa. Clin Exp Dermatol. 2022;47:1307–13. [DOI] [PubMed]

141.

Guttmann-Gruber C, Tockner B, Scharler C, Hüttner C, Common JE, Tay ASL, et al. Low-dose calcipotriol can elicit wound closure, anti-microbial, and anti-neoplastic effects in epidermolysis bullosa keratinocytes. Sci Rep. 2018;8:13430. [DOI] [PubMed] [PMC]

142.

Guttmann-Gruber C, Piñón Hofbauer J, Tockner B, Reichl V, Klausegger A, Hofbauer P, et al. Impact of low-dose calcipotriol ointment on wound healing, pruritus and pain in patients with dystrophic epidermolysis bullosa: a randomized, double-blind, placebo-controlled trial. Orphanet J Rare Dis. 2021;16:473. [DOI] [PubMed] [PMC]

143.

Molina GE, Khalifian S, Mull JL, Chen L, Rosman IS, Faulkner-Jones BE, et al. Topical combination of fluorouracil and calcipotriene as a palliative therapy for refractory extramammary paget disease. JAMA Dermatol. 2019;155:599–603. [DOI] [PubMed] [PMC]

144.

Demirkan S, Gündüz Ö, Devrim T. Sorafenib-asssociated hand-foot syndrome treated with topical calcipotriol. JAAD Case Rep. 2017;3:354–7. [DOI] [PubMed] [PMC]

145.

Wongkietkachorn K, Intarasupht J, Srisuttiyakorn C, Aunhachoke K, Nakakes A, Niumpradit N. Linear atrophoderma of moulin: a case report and review of the literature. Case Rep Dermatol. 2013;5:11–4. [DOI] [PubMed] [PMC]

146.

Ghalwash DM, Mahmoud EA, Shaker OG. Evaluation of the therapeutic effect of topical calcipotriol versus topical tretinoin in treatment of oral Leukoplakia and their effect on clinical improvement and salivary level of MMP-9, IL-6 and TGF-β: a randomized clinical trial. Egypt Dent J. 2017;63:2452–7.

147.

Elmas ÖF, Atasoy M, Akdeniz N, Özyurt K. A recalcitrant case of facial verruca plana successfully treated with topical calcipotriol alone. Dermatol Ther. 2020;33:e13664. [DOI] [PubMed]

148.

Nakamura Y, Yamaguchi M, Nakamura A, Muto M. Calcipotriol and adapalene therapy for disseminated superficial actinic porokeratosis. Indian J Dermatol Venereol Leprol. 2014;80:373–4. [DOI] [PubMed]

149.

Demitsu T, Nakamura S, Takazawa M, Kakurai M, Umemoto N, Kawase M. Axillary granular parakeratosis with osmidrosis successfully treated with topical maxacalcitol. J Dermatol. 2019;46:e155–7. [DOI] [PubMed]

150.

Bosch R, Philips N, Suárez-Pérez JA, Juarranz A, Devmurari A, Chalensouk-Khaosaat J, et al. Mechanisms of photoaging and cutaneous photocarcinogenesis, and photoprotective strategies with phytochemicals. Antioxidants (Basel). 2015;4:248–68. [DOI] [PubMed] [PMC]